علاج التخثر الجوهري للصفيحات لمن هم دون سن 60 عاماً بلا تاريخ للتخثر، وحالة JAK2 النوع البري، مع عوامل الخطر القلبية الوعائية أو طفرة CALR-1/MPL

References

DOI: 10.1002/ajh.27216

Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).

Thrombosis risk in very low risk patients with triple-negative driver mutational status is too low to warrant the need for any form of therapy, but once-daily aspirin therapy is advised in the presence of either CV risk factors or CALR-1/MPL mutations.

Very low-risk patients with ET might not require any therapy, unless in the presence of CV risk factors or CALR-1/MPL mutations, where once-daily low-dose aspirin is advised (Figure 5).

Low-dose aspirin therapy has also been shown to be effective in alleviating vasomotor (microvascular) disturbances associated with ET or PV.